The Valens Company Reports Financial Results for the Third Quarter of Fiscal 2020

KELOWNA, BC, Oct. 14, 2020 /CNW/ – The Valens Company Inc.  (TSX: VLNS) (OTCQX: VLNCF) (the “Company,” “The Valens Company” or “Valens”), a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, is pleased to report its third quarter financial results for the period ended August 31, 2020. Key Financial Highlights Net revenue for the third quarter of 2020 was $18.1 million, aContinue reading “The Valens Company Reports Financial Results for the Third Quarter of Fiscal 2020”

Flower One Announces Preliminary Q3 2020 Revenue of $11.5 Million, Exceeding Guidance for the Quarter

LAS VEGAS and TORONTO, Oct. 13, 2020 /CNW/ – Flower One Holdings Inc. (the “Company”) (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), a leading cannabis cultivator, producer and innovator in Nevada, today announced preliminary third quarter revenue of $11.5 million surpassing its Q3 2020 revenue guidance range of between $9.8 million and $10.8 million.  The Company continues to expect its Q3 2020 gross margin to be inContinue reading “Flower One Announces Preliminary Q3 2020 Revenue of $11.5 Million, Exceeding Guidance for the Quarter”

HEXO Corp. reports third quarter fiscal 2020 financial results; Net Revenue Up 30% to $22.1 Million, Improved Operational Performance

Key Operating Highlights Gross Revenue increased 30% to $30.9M from $23.8M in Q2 Net Revenue increased 30% to $22.1M from $17.0M in Q2 Adult-use grams and gram equivalents sold increased 42% to 9,338 kg compared to Q2 Gross Margins increased to 40% Operating expenses decreased to $26.8M Closed $46M public offering to enhance liquidity AdjustedContinue reading “HEXO Corp. reports third quarter fiscal 2020 financial results; Net Revenue Up 30% to $22.1 Million, Improved Operational Performance”

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

VANCOUVER, May 14, 2020 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN;OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today reported financial results for the third quarter of fiscal year 2020 (“3Q20”) which ended March 31, 2020. Conference Call &Continue reading “InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update”